Study identifies mechanism that impedes the effectiveness of melanoma therapies

FHS
June 27, 2024
4:46 pm

In many cases of malignant melanoma, the effect of targeted treatment is lost over time. A research team from UZH and USZ has now discovered that a factor secreted by tumor cells is responsible for the resistance.

Biotech VC firm outlines plans for $100M fund

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 21, 2024

COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights – Psychedelic Alpha

LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) — Highlights: COMP360 Phase 3 pivotal program ongoing and on track CPT® III code for in-person psychedelic therapy support

August 3, 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19,

December 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.